Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Taiwan · Delayed Price · Currency is TWD

137.00

-5.00 (-3.52%)

Sep 24, 2026, 1:30 PM CST

Market Cap	16.59B +35.3%
Revenue (ttm)	42.22M +22.5%
Net Income	-164.52M
EPS	-1.35
Shares Out	121.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	562,780
Open	139.00
Previous Close	142.00
Day's Range	136.50 - 141.00
52-Week Range	58.30 - 149.00
Beta	0.29
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Gongwin Biopharm Holdings

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the p... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Country Cayman Islands

Stock Exchange Taipei Exchange

Ticker Symbol 6617

Full Company Profile

Financial Performance

In 2025, Gongwin Biopharm Holdings's revenue was 36.45 million, an increase of 13.75% compared to the previous year's 32.04 million. Losses were -114.13 million, 38.3% more than in 2024.

Financial Statements